Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis
- PMID: 19139299
- DOI: 10.1001/archneurol.2008.505
Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis
Abstract
Objective: To investigate whether or not the disparity in disease progression in those with pediatric-onset compared with adult-onset multiple sclerosis (MS) is due to differences in relapse rates.
Design: Inception cohort. Mean follow-up times were 3.67 (standard deviation, 1.64) and 3.98 (standard deviation, 1.17) years in the pediatric and adult groups, respectively.
Setting: Comprehensive MS centers.
Patients: Patients with relapsing-remitting MS who were seen at the pediatric and adult MS centers at Massachusetts General and Brigham and Women's Hospitals, respectively, 12 months or less from onset of first symptom in July 2001 or later and were followed up for 12 months or longer. One hundred ten patients with adult-onset and 21 patients with pediatric-onset MS were included. Three eligible patients with adult-onset MS were excluded owing to incomplete records.
Main outcome measure: Annualized relapse rates were compared between pediatric-onset and adult-onset patients using the proportional means model.
Results: The annualized relapse rate in the pediatric-onset group was significantly higher than that in the adult-onset group (1.13 vs 0.40; P < .001) with an adjusted rate ratio of 2.81 (95% confidence interval, 2.07-3.81). When we controlled for time spent undergoing disease-modifying treatment in the analysis, the difference between the groups remained highly significant (adjusted rate ratio, 2.82; 95% confidence interval, 2.08-3.83; P < .001). When age at disease onset was treated as a continuous variable, a highly significant association between age and relapse rate was observed (P < .001).
Conclusions: Relapses are more frequent in patients with pediatric-onset compared with adult-onset MS in the disease-modifying treatment era. This finding suggests that patients with pediatric-onset MS experience a more inflammatory disease course than patients with adult onset of the disease.
Similar articles
-
Progression in familial and nonfamilial MS.Mult Scler. 2008 Apr;14(3):300-6. doi: 10.1177/1352458507084269. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208881
-
Predictors of relapse rate in MS clinical trials.Neurology. 2005 Dec 13;65(11):1769-73. doi: 10.1212/01.wnl.0000187122.71735.1f. Neurology. 2005. PMID: 16344520
-
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?Neurology. 2007 Oct 9;69(15):1498-507. doi: 10.1212/01.wnl.0000271884.11129.f3. Epub 2007 Aug 15. Neurology. 2007. PMID: 17699802
-
Predicting and preventing the future: actively managing multiple sclerosis.Pract Neurol. 2009 Jun;9(3):133-43, discussion 144. doi: 10.1136/jnnp.2009.177212. Pract Neurol. 2009. PMID: 19448055 Review.
-
Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.Eur Neurol. 2008;60(1):1-11. doi: 10.1159/000127972. Epub 2008 Apr 25. Eur Neurol. 2008. PMID: 18437041 Review.
Cited by
-
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.Neurol Sci. 2022 Jul 4. doi: 10.1007/s10072-022-06211-8. Online ahead of print. Neurol Sci. 2022. PMID: 35781765
-
Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations.Neurol Clin Pract. 2022 Jun;12(3):263-269. doi: 10.1212/CPJ.0000000000001149. Neurol Clin Pract. 2022. PMID: 35747540
-
Therapeutic Advances in Multiple Sclerosis.Front Neurol. 2022 Jun 3;13:824926. doi: 10.3389/fneur.2022.824926. eCollection 2022. Front Neurol. 2022. PMID: 35720070 Free PMC article. Review.
-
Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry.Front Neurol. 2022 Apr 18;13:851426. doi: 10.3389/fneur.2022.851426. eCollection 2022. Front Neurol. 2022. PMID: 35518208 Free PMC article.
-
Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study.BMJ Neurol Open. 2022 Feb 24;4(1):e000215. doi: 10.1136/bmjno-2021-000215. eCollection 2022. BMJ Neurol Open. 2022. PMID: 35308898 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
